Garassino M, et al. Evaluation of TMB in KEYNOTE-189: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC. Abstract OA04.06. WCLC 2019, 7-10 september, Barcelona, Spanje.,Langer C, et al. TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for non squamous NSCLC. Abstract OA04.05. WCLC 2019, 7-10 september, Barcelona, Spanje.
Famitinib met camrelizumab en nab-paclitaxel bij gevorderde tripelnegatieve borstkanker
mei 2022 | Borstkanker, Immuuntherapie